Steven Cohen’s Palvella Therapeutics PVLA Stock Holding History

Steven Cohen’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-88,160	Closed	-$11M	–	4706
2026 Q1	$11M	Buy	88,160 +10,863	+14%	+$1.13M	0.01%	1175
2025 Q4	$8.09M	Sell	77,297 -240,012	-76%	-$20.5M	0.01%	1484
2025 Q3	$19.9M	Buy	+317,309	New	+$14.2M	0.03%	550
2021 Q3	–	Sell	-12,500	Closed	-$3.83M	–	1273
2021 Q2	$3.83M	Buy	+12,500	New	+$2.74M	0.02%	653
2019 Q3	–	Sell	-4,271	Closed	-$1.61M	–	1527
2019 Q2	$1.61M	Hold	4,271	–	–	0.01%	688
2019 Q1	$1.15M	Hold	4,271	–	–	0.01%	793
2018 Q4	$909K	Buy	+4,271	New	+$1.32M	﹤0.01%	816

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Steven Cohen's PVLA Position: Q2 2026 in Review

Steven Cohen sold out of Palvella Therapeutics (PVLA) in Q2 2026, closing a stake of 88,160 shares — an estimated $11M sold.

Steven Cohen first reported a position in PVLA in Q4 2018 and held it in 7 quarters. The position peaked at $19.9M in Q3 2025. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

Steven Cohen reported no remaining Palvella Therapeutics position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 88,160 Palvella Therapeutics shares in Q2 2026, an estimated $11M.
Steven Cohen first reported a position in Palvella Therapeutics in Q4 2018 and held it in 7 quarters.
Steven Cohen's Palvella Therapeutics position peaked at $19.9M in Q3 2025.
196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.